Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease

Galafold (migalastat) - Amicus

Elfabrio (pegunigalsidase alfa-iwxj) - Protalix, Chiesi

Replagal (agalsidase alfa) - Samaritan Pharma, Takeda

https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2025/program/program/paper/ispor-europe-2025/poster-session-3-2/matching-adjusted-indirect-comparisons-maics-and-network-meta-analyses-nmas-of-the-oral-small-molecule-chaperone-migalastat-vs-intravenous-enzyme-replacement-therapies-erts-for-clinical-measures-in-fabry-disease

Noemi Hummel, PhD 1; Agnieszka Kopiec, MSc 2; Matthew Crabtree, MPH 3; Alasdair MacCulloch, BSc, PhD 3; Charlotte Sharples, MD 3; Biliana O. Veleva-Rotse, PhD 4; Neil Johnson, BSc 3; Vera Gielen, PhD 3.

Nov 11, 2025